Penicillamine vs Leflunomide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Antirheumatic Agent

Penicillamine

Brand: AAGYLUR

First FDA approval: 1970-12-04

Antirheumatic Agent

Leflunomide

Brand: Arava

First FDA approval: 1998-09-10

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$0.288Per unit

Average NADACAcross all dosage forms and strengths

—

$0.309Up to $0.330

Generic manufacturersActive ANDA holders — FDA Orange Book

89 total ANDAs filed

918 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$15.9MFull year

$54.0MFull year

Part D claims (CY24)Total fills, all strengths

2K434 beneficiaries

873K272K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$7,161Per claim, all NDCs

$62Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

102Substantial friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

3Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes9 manufacturers